williamÍþÁ®ÑÇÖÞ¹Ù·½

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞ·þÎñ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ
Jun 28,2023
Éè¼ÆºÏ³ÉһϵÁÐDHODHÒÖÖƼÁ×÷ΪDZÔÚµÄÀà·çʪÐÔÊàŦÑ×ÖÎÁÆÒ©ÎPKÑо¿Í¨¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
Human dihydroorotate dehydrogenase (DHODH) is a viable target for the development of therapeutics to treat cancer and immunological diseases. Herein, researchers designed and synthesized a series of acrylamide-based novel DHODH inhibitors as potential rheumatoid arthritis (RA) treatment agents.
Éó²é¸ü¶à
Éè¼ÆºÏ³ÉһϵÁÐDHODHÒÖÖƼÁ×÷ΪDZÔÚµÄÀà·çʪÐÔÊàŦÑ×ÖÎÁÆÒ©ÎPKÑо¿Í¨¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
Jun 28,2023
¿ª·¢²¢Ñé֤еÄLC-MS/MSÒªÁ죬ÓÃÓÚ¶¨Á¿ÈËѪ½¬ÖдïÀ­·ÇÄá¼°ÆäÖ÷Òª´úлÎïôÇ»ù´ïÀ­·ÇÄá (OHD)¡£OHD£¨´¿¶È>99%£©Í¨¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½ºÏ³É
OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
Éó²é¸ü¶à
¿ª·¢²¢Ñé֤еÄLC-MS/MSÒªÁ죬ÓÃÓÚ¶¨Á¿ÈËѪ½¬ÖдïÀ­·ÇÄá¼°ÆäÖ÷Òª´úлÎïôÇ»ù´ïÀ­·ÇÄá (OHD)¡£OHD£¨´¿¶È>99%£©Í¨¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½ºÏ³É
Jun 28,2023
·ÅÉäÁÆ·¨ÓÃ×÷·Î°©µÄÖ÷ÒªÖÎÁÆÒªÁ죬ÔÚ´ÎÑо¿Öн¨É迹µçÀë·øÉä·Î°©Ï¸°ûϵµÄ·ÅÉäÖÎÁÆͨ¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.
Éó²é¸ü¶à
·ÅÉäÁÆ·¨ÓÃ×÷·Î°©µÄÖ÷ÒªÖÎÁÆÒªÁ죬ÔÚ´ÎÑо¿Öн¨É迹µçÀë·øÉä·Î°©Ï¸°ûϵµÄ·ÅÉäÖÎÁÆͨ¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
Jun 28,2023
CAR-TÁÆ·¨Ö÷ÒªÕë¶Ô°×Ѫ²¡Óë¶ñÐÔÁÜ°ÍÁö£¬´ËÑо¿Öй¹½¨Ä¬È»PD-1µÄshRNAÔØÌåÖÊÁ££¬²âÐòºóÖÊÁ£µÄÅжÏͨ¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.
Éó²é¸ü¶à
CAR-TÁÆ·¨Ö÷ÒªÕë¶Ô°×Ѫ²¡Óë¶ñÐÔÁÜ°ÍÁö£¬´ËÑо¿Öй¹½¨Ä¬È»PD-1µÄshRNAÔØÌåÖÊÁ££¬²âÐòºóÖÊÁ£µÄÅжÏͨ¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
Jun 28,2023
Ë÷À­·ÇÄáµÄÎÞ¶¨ÐιÌÌåÊèÉ¢ÌåÓÃÓÚ¿ª·¢¸ÄÁ¼ÐÍ¿Ú·þÉúÎïʹÓöȸߵÄËÙÊÍƬ¼Á£¬PKÑо¿Í¨¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar?. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar? tablets was performed by Medicilon.
Éó²é¸ü¶à
Ë÷À­·ÇÄáµÄÎÞ¶¨ÐιÌÌåÊèÉ¢ÌåÓÃÓÚ¿ª·¢¸ÄÁ¼ÐÍ¿Ú·þÉúÎïʹÓöȸߵÄËÙÊÍƬ¼Á£¬PKÑо¿Í¨¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
Jun 28,2023
TAK-931ÊÇÒ»Öָ߶ÈÌØÒìÐÔµÄCDC7ÒÖÖƼÁ£¬¾ßÓп¹Ö×Áö¹¦Ð§£¬ÌåÄÚҩЧÑо¿Í¨¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.
Éó²é¸ü¶à
TAK-931ÊÇÒ»Öָ߶ÈÌØÒìÐÔµÄCDC7ÒÖÖƼÁ£¬¾ßÓп¹Ö×Áö¹¦Ð§£¬ÌåÄÚҩЧÑо¿Í¨¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
Jun 28,2023
GS-5801ÊÇÒ»ÖÖÓÐÓõÄKDM5ÒÖÖƼÁ£¬¾ßÓп¹HBV»îÐÔ£¬GS-5801ͨ¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½ºÏ³É
GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.
Éó²é¸ü¶à
GS-5801ÊÇÒ»ÖÖÓÐÓõÄKDM5ÒÖÖƼÁ£¬¾ßÓп¹HBV»îÐÔ£¬GS-5801ͨ¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½ºÏ³É
Jun 28,2023
QF-036ÊÇÒ»ÖÖ¸ßЧµÄHIV-1ÒÖÖƼÁ£¬¾ßÓÐÓÅÒìµÄºÍÒ©´ú¶¯Á¦Ñ§ÌØÕ÷£¬PKÑо¿Í¨¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.
Éó²é¸ü¶à
QF-036ÊÇÒ»ÖÖ¸ßЧµÄHIV-1ÒÖÖƼÁ£¬¾ßÓÐÓÅÒìµÄºÍÒ©´ú¶¯Á¦Ñ§ÌØÕ÷£¬PKÑо¿Í¨¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
Jun 28,2023
Éè¼ÆºÏ³ÉÒ»ÖÖÐÂÐÍÑ¡ÔñÐԵĿڷþÓÐÓÃËÕ°±ËáÀÒ°±Ëἤø (TTK) ÒÖÖƼÁ£¬PKÑо¿¾ùͨ¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon.
Éó²é¸ü¶à
Éè¼ÆºÏ³ÉÒ»ÖÖÐÂÐÍÑ¡ÔñÐԵĿڷþÓÐÓÃËÕ°±ËáÀÒ°±Ëἤø (TTK) ÒÖÖƼÁ£¬PKÑо¿¾ùͨ¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
Jun 28,2023
TR-107ÊÇÈËÀàÏßÁ£ÌåÂÑ°×øClpPµÄÓÐÓü¤»î¼Á£¬PKÆÊÎöͨ¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
The pharmacokinetic properties of TR©\107 were compared with other known ClpP activators including ONC201 and ONC212. TR©\107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic properties in ICR mice by Medicilon.
Éó²é¸ü¶à
TR-107ÊÇÈËÀàÏßÁ£ÌåÂÑ°×øClpPµÄÓÐÓü¤»î¼Á£¬PKÆÊÎöͨ¹ýwilliamÍþÁ®ÑÇÖÞ¹Ù·½¾ÙÐÐ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
ÍøÕ¾µØͼ
ÓÑÇéÁ´½Ó£ºyd2333Ôƶ¥µç×ÓÓÎÏ·  Íþ¿Íµç¾º  yd2333Ôƶ¥µç×ÓÓÎÏ·  js1996¹ÙÍø  fun88¹ÙÍø  É³°Í¹ÙÍø  ÀÖÌìÌÃfun88  amjs°Ä½ðɳÃÅ  ×ðÁú¿­Ê±  Ê®´óµç×ÓÓÎϷƽ̨ÍøÕ¾  Íþ¿Íµç¾º  k8¿­·¢agÆì½¢  ca88¹ÙÍø  ºìÊÀÒ»×ã  ¹ÅÌìÀÖÌ«ÑôÓéÀÖ¼¯ÍÅ